PF-Atlas › Clinical Trials › NCT00705133

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

Treprostinil · Phase 2

Registry ID
NCT00705133
Phase
Phase 2
Status
Completed
Drug / intervention
Treprostinil
Sponsor
Rajan Saggar
Start
2008-07
Enrollment
15
Locations
1

About this trial

Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.

View NCT00705133 on ClinicalTrials.gov →

Explore related

Inhaled Treprostinil / Tyvaso — Treatment profileAll Treprostinil trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00705133 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.